HOME >> BIOLOGY >> NEWS
Recycling is not enough -- we need to consume less

Recycling rates have risen, and the UK is on schedule to meet EU targets, but the key to dealing with our escalating waste problem lies in changing our buying habits and our attitudes to consumption, according to the authors of a new Economic and Social Research Council (ESRC) publication.

Consumption: reducing, reusing and recycling, which accompanied a seminar in Belfast organised jointly with the Office of the First Minister and Deputy First Minister, Northern Ireland, says that the benefits of recycling risk being undermined by the sheer quantity of waste being generated. If household waste output continues to rise by three per cent a year, the cost to the economy will be 3.2 billion and the amount of harmful methane emissions will double by 2020.

The report highlights the many ways that social science can contribute to waste policy development, either by devising initiatives, by providing tools to evaluate their relative effectiveness or by helping understand why they did or did not work.

Professor Ken Peattie, Director of the ESRC Centre for Business Relationships, Accountability, Sustainability and Society (BRASS), Cardiff University, describes three projects which are linked to different aspects of waste reduction at the production stage and in consumption. He says the key tool in the development and implementation of consumption reduction policies is social marketing, which involves using commercial marketing techniques to influence their behaviour for the benefit of society as a whole.

Ken Peattie explains that social marketing can be successful because it focuses on the target audiences point of view, taking account of any emotional or physical barriers that may prevent people from changing their behaviour. 'Guilt messages are ineffective. A focus on the benefits of a greener lifestyle has been shown to be a better way to encourage people to reduce their consumption,' the report says.

Ben Shaw, Senior
'"/>

Contact: Annika Howard
PressOffice@esrc.ac.uk
44-017-934-13119
Economic & Social Research Council
15-Jun-2007


Page: 1 2

Related biology news :

1. Recycling of aeronautics components
2. MIT: Recycling of scrapped electronics studied
3. One Wwox isnt enough (to protect against cancer)
4. Its enough to turn your neighbors green
5. Successful lung cancer surgery not enough to break nicotine dependence in many smokers
6. When Gleevec is not enough
7. Marine life stirs ocean enough to affect climate, says FSU study
8. Increase in drug development for killer diseases is not enough
9. Heart has enough oxygen to survive hypothermia, CPR crucial
10. Pepper component hot enough to trigger suicide in prostate cancer cells
11. Yale study: Not enough metals in earth to meet global demand

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Recycling not enough need consume less

(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... to the antibiotic colistin are also commonly resistant ... according to a study in mBio , ... for Microbiology. Cross-resistance to colistin and host antimicrobials ... against bacterial attack, could mean that patients with ... a crippled immune response. Colistin is a last-line ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: